Small interfering RNA targeting integrin-linked kinase inhibited the growth and induced apoptosis in human bladder...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Integrin-linked kinase (ILK) is a serine/threonine kinase involved in cell growth, survival, and apoptosis.
• ILK expression and activity are elevated in various solid tumors, but its precise role in tumorigenesis remains unclear.
• Bladder cancer progression involves dysregulated cell growth and apoptosis.

Purpose of the Study:

• To investigate the effect of ILK knockdown on bladder cancer cell proliferation and apoptosis.
• To elucidate the molecular mechanisms by which ILK influences bladder cancer progression.
• To evaluate ILK as a potential therapeutic target for bladder cancer.

Main Methods:

• Utilized plasmid vector-based small interfering RNA (siRNA) to achieve ILK knockdown in bladder cancer cell lines (BIU-87 and EJ).
• Assessed cell proliferation, cell cycle regulation, and apoptosis using various assays.
• Analyzed the phosphorylation status of downstream targets (Akt, GSK-3β) and expression of β-catenin and Ribonuclease inhibitor (RI) via Western blot and immunofluorescence.
• Evaluated tumor growth inhibition in a xenograft mouse model (BALB/C nude mice).

Main Results:

• ILK knockdown significantly inhibited proliferation and induced apoptosis in BIU-87 and EJ bladder cancer cells.
• Downregulation of ILK reduced phosphorylation of Akt and GSK-3β and decreased β-catenin expression.
• ILK inhibition led to increased expression of Ribonuclease inhibitor (RI).
• In vivo studies showed reduced tumor weight, decreased microvessel density, and higher apoptosis rates in mice treated with ILK siRNA.

Conclusions:

• ILK plays a crucial role in bladder cancer cell growth, survival, and progression.
• Targeting ILK effectively inhibits bladder cancer development and induces apoptosis.
• ILK represents a promising therapeutic target for human bladder cancer, with potential clinical significance.